Ashley Watson Biography and Net Worth

SVP of Merck & Co., Inc.

Ashley Watson is vice president and chief ethics and compliance officer at HP, overseeing the strategy and implementation of HP’s ethics and compliance program, including adherence to the Standards of Business Conduct. Her team is also responsible for social and environmental sustainability and compliance, privacy, global records management and the HP Foundation.

Previously, she led the Global Functions legal team responsible for providing legal support to HR, CASS, IT and Corporate Marketing. The Global Functions legal
group, like its functional clients, partners closely with other legal groups to ensure seamless risk assessment and advice.

Before joining HP in December 2008, Watson was Vice President, General Counsel and Corporate Secretary at Attenex, responsible for all company legal matters, including M&A, strategic alliances, IP Policy, risk management and compliance, managing members of the legal department and overseeing outside counsel. She was previously senior litigation Counsel at BellSouth Corporation, responsible for complex litigation.

Watson holds a J.D. degree from the University of Georgia and her undergraduate degree from the University of North Carolina at Chapel Hill.

What is Ashley Watson's net worth?: The estimated net worth of Ashley Watson is at least $3.19 million as of October 31st, 2018. Ms. Watson owns 32,990 shares of Merck & Co., Inc. stock worth more than $3,185,514 as of November 19th. This net worth approximation does not reflect any other investments that Ms. Watson may own. Learn More about Ashley Watson's net worth.
How do I contact Ashley Watson?: The corporate mailing address for Ms. Watson and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Ashley Watson's contact information.
Has Ashley Watson been buying or selling shares of Merck & Co., Inc.?: Ashley Watson has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Ashley Watson sold 47,036 shares of the business's stock in a transaction on Wednesday, October 31st. The shares were sold at an average price of $74.33, for a transaction totalling $3,496,185.88. Following the completion of the sale, the senior vice president now directly owns 32,990 shares of the company's stock, valued at $2,452,146.70. Learn More on Ashley Watson's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Ashley Watson Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/31/2018	Sell	47,036	$74.33	$3,496,185.88	32,990

Ashley Watson Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $96.56

$95.42

$97.29

50 Day Range

MA: $108.46

$96.30

$118.68

2 Week Range

Now: $96.56

$94.48

$134.63

Volume

14,139,870 shs

Average Volume

8,932,278 shs

Market Capitalization

$244.26 billion

P/E Ratio

20.24

Dividend Yield

3.13%

Beta

0.4

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.